Loading people...
Carl Decicco is a Partner at Flagship Pioneering, a leading venture creation firm. He is known for his extensive experience in drug discovery and development, playing a key role in conceiving and building innovative life science companies.
Carl Decicco, as a Partner at Flagship Pioneering, focuses on creating and developing groundbreaking life science companies from novel scientific concepts. His work involves identifying opportunities in areas like drug discovery, immunology, oncology, and rare diseases, rather than traditional investments in existing companies.
Carl Decicco works as a Partner at Flagship Pioneering, a venture creation firm headquartered in Cambridge, Massachusetts. Flagship Pioneering is dedicated to originating and building transformative companies in the life sciences sector.
Carl Decicco is a Partner at Flagship Pioneering based in New Hope, Pennsylvania. Before joining the venture creation firm in 2018, he served as Chief Scientific Officer at Foghorn Therapeutics and spent nearly two decades at Bristol-Myers Squibb, culminating in his role as Senior Vice President and Head of Discovery. During his biopharmaceutical career, he has advanced more than 200 compounds into clinical trials and contributed to over 20 drug approvals across small molecules and biologics. He holds a doctorate in organic chemistry from the University of Guelph and completed postdoctoral research at Harvard University and the University of British Columbia. Additionally, he has authored over 100 peer-reviewed scientific papers and holds 26 patents. His current focus centers on advising early-stage portfolio companies and driving scientific strategy within the biotechnology and life sciences sectors.
Carl Decicco is a distinguished Partner at Flagship Pioneering, a unique venture creation firm renowned for its pioneering approach to building breakthrough companies from scientific innovation. In his role, Mr. Decicco is instrumental in the firm's core mission: identifying and nurturing revolutionary scientific concepts into viable, impactful enterprises. His expertise is particularly focused on the intricate process of drug discovery and development, where he applies decades of experience to guide the creation of novel therapeutic platforms and solutions.
At Flagship Pioneering, Carl Decicco is deeply involved in the entire company creation lifecycle. This includes the initial ideation phase, where he collaborates with scientists and entrepreneurs to explore uncharted biological territories and identify opportunities for paradigm-shifting advancements. He then helps to build the foundational science, recruit leadership teams, and secure initial funding, transforming nascent ideas into robust, independently operating companies. His strategic insights are crucial in shaping the scientific direction and business strategy of these emerging ventures, ensuring they are poised for success in the competitive life sciences landscape.
Prior to joining Flagship Pioneering, Carl Decicco built an impressive career marked by significant leadership roles in pharmaceutical research and development. He served as Senior Vice President and Head of Discovery and Early Clinical Development at Pfizer, a global pharmaceutical giant. In this capacity, he oversaw critical stages of drug development, from initial discovery through early clinical trials, contributing to the advancement of numerous potential therapies. Before his tenure at Pfizer, Mr. Decicco held various leadership positions at Bristol-Myers Squibb, where he was instrumental in driving drug discovery efforts across multiple therapeutic areas.
Mr. Decicco's academic background is equally robust, holding a Ph.D. in Organic Chemistry from the University of Pennsylvania. He further honed his scientific acumen as a Postdoctoral Fellow at Harvard University, solidifying his foundation in cutting-edge research. This deep scientific expertise, combined with his extensive industry leadership, makes him a formidable force in identifying and cultivating the next generation of life science breakthroughs. While Flagship's model focuses on company creation rather than traditional investments, Carl Decicco has been pivotal in the genesis and early development of numerous Flagship-founded companies, contributing to their scientific strategy and operational build-out, ultimately aiming to deliver transformative medicines to patients worldwide.
